 HC Wainwright restated their neutral rating on shares of Eloxx Pharmaceuticals OTCMKTS:ELOX in a research report sent to investors on Friday morning, The Fly reports. The brokerage currently has a 3.00 target price on the stock, down from their previous target price of 10.00. Separately, Zacks Investment Research cut Eloxx Pharmaceuticals from a buy rating ... 